Skip to content

News

Accelerating dementia clinical trials through partnership

A recent study, led by UKDTN’s Director – Professor Catherine Mummery – evaluated ImmunoBrain’s IBC-Ab002, a monoclonal antibody designed to modulate immune responses associated with Alzheimer’s Disease and support the brain’s repair processes.

Results from the phase 1b trial, shared at ADPD 2026 in Copenhagen, involved 40 participants with early Alzheimer’s Disease across the UK, the Netherlands and Israel.

The ImmunoBrain study was among first trials led by UKDTN, enabling coordinated delivery across several UK sites and demonstrating the value of a national, harmonised trial infrastructure. The drug was found to be safe and well tolerated, with early biomarker signals showing promise to impact on the course of the disease.

For more information on this trial, visit: https://immunobrain.com/lead-program/ibc-ab002-antibody/

Other News

ARUK-UKDTN Partnership

Applications open for ARUK Doctoral Clinical Fellowship and UKDTN Clinical Trial Placement Pilot Clinicians interested in building a career in dementia clinical research are invited to apply for the Alzheimer’s Research
Click here for full report
UKDTNAdminBy UKDTNAdmin

UKDTN strengthens global partnerships at AAIC 2026 in London

UKDTN was proud to participate in the Alzheimer’s Association International Conference (AAIC) 2026, held in London. Bringing together more than 10,000 researchers, clinicians, industry leaders and healthcare professionals from across the
Click here for full report
UKDTNAdminBy UKDTNAdmin
« Prev123456Next »
×

Privacy Notice: This site uses no tracking or marketing cookies by default. Non-essential cookies are only used if you choose to play embedded videos. We prioritise a simple and secure experience. Cookie Policy.